Peter McCullough, MD, Cardiology, Dallas, TX, Ascension of Providence Hospital, Southfield Campus

PeterAndrewMcCulloughMDMPH

Cardiology Dallas, TX

Adult Congenital Heart Disease, Non-Invasive Cardiology, Preventive Cardiology, Cardiovascular Disease Genetics

Professor of Medicine, Vice Chief of Internal Medicine, Cardiology Program Director

Dr. McCullough is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. McCullough's full profile

Already have an account?

Summary

  • Dr. McCullough is a consultant cardiologist and Vice Chief of Internal Medicine at Baylor University Medical Center and Professor of Medicine at Texas A & M College of Medicine. Dr. McCullough is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with > 1000 publications and > 550 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, British Medical Journal and other top-tier journals worldwide. He is the editor-in-chief of Cardiorenal Medicine, Reviews in Cardiovascular Medicine, and senior associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), European Medicines Agency, and the U.S. Congressional Oversight Panel.

Education & Training

  • William Beaumont Hospital
    William Beaumont HospitalFellowship, Cardiovascular Disease, 1994 - 1997
  • University of Michigan School of Public HealthM.P.H., General Epidemiology, 1994
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 1988 - 1991
  • University of Texas Southwestern Medical School
    University of Texas Southwestern Medical SchoolClass of 1988
  • Baylor UniversityB.S., Double-major: Biology and Psychology, With Honors, 1984

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2014 - 2022
  • MI State Medical License
    MI State Medical License 1991 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • President Cardiorenal Society of America
  • 11th International Vicenza Award in Critical Care Nephrology International Renal Research Institute, 2013
  • Fellow National Lipid Association, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Review of the Use of Iloprost, A Synthetic Prostacyclin, in the Prevention of Radiocontrast Nephropathy in Patients Undergoing Coronary Angiography and Intervention  
    Kassis HM, Minsinger KD, McCullough PA, Block CA, Sidhu MS, Brown JR, Clin Cardiol, 1/12/2015
  • Efficacy and safety of alirocumab in reducing lipids and cardiovascular events  
    Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kas..., N Engl J Med, 1/1/2015
  • Novel Agents for the Prevention and Management of Hyperkalemia  
    McCullough PA, Costanzo MR, Silver M, Spinowitz B, Zhang J, Lepor NE, Rev Cardiovasc Med, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Novel Agents for the Prevention and Management of Hyperkalemia.
    McCullough PA, Spinowitz B, Journal of Managed Care and Speciality Pharmacy, 1/1/2015
  • Vadadustat, a Novel Oral Treatment for Anemia of Chronic Kidney Disease, Maintains Stable Hemoglobin Levels in Dialysis Patients Converting from Erythropoiesis-Stimula...
    Haase VH, Hartman CS, Maroni BJ, Farzaneh-Far R, McCullough PA, J Am Soc Nephrol, 1/1/2015
  • Subclinical and clinical contrast-induced acute kidney injury: results from the ENCINO Study.
    Akrawinthawong K, Parker G, Stivers D, Cannon L, Dixon S, Ricci J, Kupfer K, Alexander P, David S, McCullough PA, Am J Kidney Dis, 1/1/2014
  • Join now to see all

Lectures

  • Speaker 
    2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
  • Heart and Kidney: a Dangerous Liaison 
    University of Sienna, Sienna, Italy - 1/29/2015
  • Lp-PLA2 as a marker of Vascular Inflammation and CHD Risk Assessment 
    Atlanta, GA - 1/29/2015
  • Join now to see all

Other

  • Case Study: Sudden Death in Marathon Runners: Pathophysiology and Diagnosis 
    McCullough PA, Trivax JE, with Conti CR, ACCEL Audio Journal
    1/1/2012
  • Kidney disease can be a sign of heart disease. 
    McCullough PA, Bottom Line Personal
    1/15/2007
  • Safety Concerns Trump Public Health Benefit in the Eyes of the FDA Cardiorenal Panel. FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For ... 
    McCullough PA, GLG NewsWatch
    www.medicalnewstoday.com
    1/14/2007
  • Join now to see all

Authored Content

  • The AHA Is Taking Ambulatory Care During COVID-19 to HeartNovember 2020
  • CHEST 2020: COVID-19 and Our CommunityOctober 2020
  • Cardiovascular Risk Reduction in Patients with Chronic Kidney Disease Potential for Targeting Inflammation with CanakinumabMay 2018
  • Cardiovascular Risk Reduction in Patients with Chronic Kidney Disease Potential for Targeting Inflammation with CanakinumabMay 2018
  • Interpreting the Wide Range of NT-proBNP Concentrations in Clinical Decision MakingMarch 2018
  • Join now to see all

Press Mentions

  • Dr. George Fareed and Colleagues Urge Early Outpatient Treatment for COVID-19
    Dr. George Fareed and Colleagues Urge Early Outpatient Treatment for COVID-19January 12, 2021 12:32
  • Early Treatment Can Stem the Tide of COVID-19 Hospitalizations and Deaths, States the Association of American Physicians & Surgeons (AAPS)
    Early Treatment Can Stem the Tide of COVID-19 Hospitalizations and Deaths, States the Association of American Physicians & Surgeons (AAPS)January 01, 2021 11:21
  • UW’s WWAMI Medical Education Program Benefits from Local Physician Volunteers’ Experiences
    UW’s WWAMI Medical Education Program Benefits from Local Physician Volunteers’ ExperiencesDecember 15, 2020 11:49
  • Join now to see all

Professional Memberships

Hospital Affiliations